Alex Fonollosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alex Fonollosa has a total of 258 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Adán
Department of Ophthalmology, Hospital Clinic of Barcelona, 08036 Barcelona, Spain
5 shared publications Joseba Artaraz
Department of Ophthalmology, Biocruces Bizkaia Health Research Institute, Cruces University Hospital, University of the Basque Country
5 shared publicationsAlfredo Adan
Ophthalmology Department, Institut Clinic de Barcelona, Autonoma University, Barcelona, Spain
3 shared publicationsLaura Pelegrín
Ocular Inflammation Unit, Department of Ophthalmology, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
3 shared publications- Lena Giralt
Univ Barcelona, Hosp Clin Barcelona, Dept Ophthalmol, Sabino Arana 1, Barcelona 08028, Spain
3 shared publications - Victor Llorenç
Hospital Clínic de Barcelona
3 shared publications
Latest Publications
- Open Access
- 3 May 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 288, 207-219
Imaging Biomarkers for Early Differentiation of Candida and Aspergillus Endogenous Fungal Endophthalmitis: Multicenter Optical Coherence Tomography-Based Analysis
- 3 May 2026
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 288, 207-219
Open AccessImaging Biomarkers for Early Differentiation of Candida and Aspergillus Endogenous Fungal Endophthalmitis: Multicenter Optical Coherence Tomography-Based Analysis
- Open Access
- 6 March 2026
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (10) , 1189-1194
Iberian Registry of Ocular Syphilis (IBERSOS) report 1: epidemiology, clinical spectrum and treatment outcomes of ocular syphilis in the Iberian Peninsula
Purpose The Iberian Registry of Ocular Syphilis aims to describe the epidemiology, clinical manifestations and treatment outcomes of ocular syphilis in Spain and Portugal. This re-emerging condition, associated with rising global syphilis rates and HIV coinfection, presents with diverse ocular and systemic features. The study seeks to fill knowledge gaps regarding incidence, presentation and therapeutic response. Methods This multicentre, observational cohort study includes patients aged ≥18 years with newly diagnosed ocular syphilis confirmed by treponemal and nontreponemal serological tests. Conducted across 23 centres, data collection followed routine clinical practice and included demographics, ocular/systemic findings, treatment regimens and outcomes at 3–6 months post-treatment. Results In the first year, 41 patients met the inclusion criteria, of whom 39 consented to participate in the registry, with an incidence of 0.57 cases per 100 000 persons/year. Most were male (94.9%), especially men who have sex with men (66.7%) and HIV coinfection (20.5%). Bilateral ocular involvement was observed in 64.1% of patients, with anterior segment inflammation in 64.1%, vitritis in 53.8%, retinal or choroidal involvement in 69.2% and optic nerve involvement in 59.0%. Systemic syphilis stage included primary (7.7%), secondary (25.6%) and tertiary or quaternary (15.4%). Treatment was initiated after a mean of 6.2±9.3 weeks after the onset of symptoms, and 2.6±6.0 weeks after the initial presentation at the hospital. Intravenous penicillin G was used in 65.8%, and 61.3% achieved a four-fold titre reduction in the reaginic test at the final visit (3 to 6 months after antibiotic therapy). Final visual acuity improved to 0.17 LogMAR (pConclusions Ocular syphilis in the Iberian Peninsula shows a wide clinical spectrum and frequent posterior segment involvement. Most patients achieved favourable serological and visual outcomes. These findings support the effectiveness of standard therapies and highlight the need for early diagnosis, especially in high-risk populations.
- 6 March 2026
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (10) , 1189-1194
Open AccessIberian Registry of Ocular Syphilis (IBERSOS) report 1: epidemiology, clinical spectrum and treatment outcomes of ocular syphilis in the Iberian Peninsula
Purpose The Iberian Registry of Ocular Syphilis aims to describe the epidemiology, clinical manifestations and treatment outcomes of ocular syphilis in Spain and Portugal. This re-emerging condition, associated with rising global syphilis rates and HIV coinfection, presents with diverse ocular and systemic features. The study seeks to fill knowledge gaps regarding incidence, presentation and therapeutic response. Methods This multicentre, observational cohort study includes patients aged ≥18 years with newly diagnosed ocular syphilis confirmed by treponemal and nontreponemal serological tests. Conducted across 23 centres, data collection followed routine clinical practice and included demographics, ocular/systemic findings, treatment regimens and outcomes at 3–6 months post-treatment. Results In the first year, 41 patients met the inclusion criteria, of whom 39 consented to participate in the registry, with an incidence of 0.57 cases per 100 000 persons/year. Most were male (94.9%), especially men who have sex with men (66.7%) and HIV coinfection (20.5%). Bilateral ocular involvement was observed in 64.1% of patients, with anterior segment inflammation in 64.1%, vitritis in 53.8%, retinal or choroidal involvement in 69.2% and optic nerve involvement in 59.0%. Systemic syphilis stage included primary (7.7%), secondary (25.6%) and tertiary or quaternary (15.4%). Treatment was initiated after a mean of 6.2±9.3 weeks after the onset of symptoms, and 2.6±6.0 weeks after the initial presentation at the hospital. Intravenous penicillin G was used in 65.8%, and 61.3% achieved a four-fold titre reduction in the reaginic test at the final visit (3 to 6 months after antibiotic therapy). Final visual acuity improved to 0.17 LogMAR (pConclusions Ocular syphilis in the Iberian Peninsula shows a wide clinical spectrum and frequent posterior segment involvement. Most patients achieved favourable serological and visual outcomes. These findings support the effectiveness of standard therapies and highlight the need for early diagnosis, especially in high-risk populations.
- 23 February 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 148, 106795
Peripheral ulcerative keratitis (PUK) in autoimmune diseases: a severe ocular manifestation not always associated with systemic disease activity
- 23 February 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 148, 106795
Peripheral ulcerative keratitis (PUK) in autoimmune diseases: a severe ocular manifestation not always associated with systemic disease activity
- Open Access
- 21 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1745948
Revisiting pathologic myopia: imaging evidence of an inflammatory component in the pathogenesis of myopic degeneration
Pathologic myopia has traditionally been viewed as a degenerative disorder caused by mechanical stretching and choroidal ischemia. However, converging clinical, molecular, and imaging data increasingly suggest that chronic low-grade inflammation contributes to both the onset and progression of myopic retinal degeneration. Recent studies have identified inflammatory patterns—including multifocal choroiditis/punctate inner choroidopathy (MFC/PIC)–like lesions, periatrophic inflammatory “plumes,” and secondary Multiple Evanescent White Dots Syndrome (MEWDS)—often localized at sites of retinal pigment epithelium–Bruch’s membrane disruption. Parallel laboratory evidence indicates dysregulation of cytokines, activation of the complement cascade, and engagement of intracellular signaling pathways such as JAK–STAT within the myopic eye. Together, these findings support a model in which mechanical stress and hypoxia act as triggers for sustained immune activation, promoting extracellular-matrix remodeling, choroidal thinning, and progressive atrophy. Recognizing inflammation as an integral component of the pathophysiology of pathologic myopia may open new therapeutic perspectives, including immunomodulatory or complement-targeting approaches.
- 21 January 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1745948
Open AccessRevisiting pathologic myopia: imaging evidence of an inflammatory component in the pathogenesis of myopic degeneration
Pathologic myopia has traditionally been viewed as a degenerative disorder caused by mechanical stretching and choroidal ischemia. However, converging clinical, molecular, and imaging data increasingly suggest that chronic low-grade inflammation contributes to both the onset and progression of myopic retinal degeneration. Recent studies have identified inflammatory patterns—including multifocal choroiditis/punctate inner choroidopathy (MFC/PIC)–like lesions, periatrophic inflammatory “plumes,” and secondary Multiple Evanescent White Dots Syndrome (MEWDS)—often localized at sites of retinal pigment epithelium–Bruch’s membrane disruption. Parallel laboratory evidence indicates dysregulation of cytokines, activation of the complement cascade, and engagement of intracellular signaling pathways such as JAK–STAT within the myopic eye. Together, these findings support a model in which mechanical stress and hypoxia act as triggers for sustained immune activation, promoting extracellular-matrix remodeling, choroidal thinning, and progressive atrophy. Recognizing inflammation as an integral component of the pathophysiology of pathologic myopia may open new therapeutic perspectives, including immunomodulatory or complement-targeting approaches.
- Open Access
- 16 January 2026
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (8) , 892-898
Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project
Aim: To explore associations between artificial intelligence (AI)-based baseline optical coherence tomography (OCT) fluid compartment quantifications and 12-month visual outcomes in diabetic macular oedema (DME) eyes treated with the intravitreal dexamethasone implant. Methods: This was a multicentre, real-world, national DME database and associated OCT dataset study. Demographics, visual acuity (VA), treatments and visit data were collected using a validated web-based tool (Fight Retinal Blindness). Fluid compartment quantifications, including intraretinal fluid (IRF) and subretinal fluid (SRF), were measured in nanolitres (nL) using a validated AI tool (Discovery). Univariate and multivariate regression mixed models evaluated associations between anatomical variables and VA outcomes. Results: A total of 101 treatment-naïve DME eyes were grouped into quartiles according to their fluid volume for each fluid compartment (Q1: lowest volume, Q4: highest volume). Baseline IRF was associated with greater VA gains at month 12 (+6.34 letters, p=0.07) but poorer final VA (−8.95, p=0.07), while SRF was associated with worse final VA at 12 months (−12.5, p=0.01). At month 3, IRF was associated with a VA decrease at 12 months (−13.7, p=0.02) and lower final VA (−29.8, p<0.001). At month 12, IRF was associated with lower final VA (−11.6, p=0.03). Quantitatively, a reduction of 100 nL of IRF at 3 months was associated with a +1.54 letters gain (p=0.03) in the multivariate analysis. Conclusion: This real-world, multicentre study describes objective baseline fluid volumes that predict visual outcomes at 12 months in routine clinical care. Accurate quantification of baseline fluid volumes may play a predictive role for final visual outcomes.
- 16 January 2026
- Published by BMJ in British Journal of Ophthalmology
- Vol. 110 (8) , 892-898
Open AccessArtificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project
Aim: To explore associations between artificial intelligence (AI)-based baseline optical coherence tomography (OCT) fluid compartment quantifications and 12-month visual outcomes in diabetic macular oedema (DME) eyes treated with the intravitreal dexamethasone implant. Methods: This was a multicentre, real-world, national DME database and associated OCT dataset study. Demographics, visual acuity (VA), treatments and visit data were collected using a validated web-based tool (Fight Retinal Blindness). Fluid compartment quantifications, including intraretinal fluid (IRF) and subretinal fluid (SRF), were measured in nanolitres (nL) using a validated AI tool (Discovery). Univariate and multivariate regression mixed models evaluated associations between anatomical variables and VA outcomes. Results: A total of 101 treatment-naïve DME eyes were grouped into quartiles according to their fluid volume for each fluid compartment (Q1: lowest volume, Q4: highest volume). Baseline IRF was associated with greater VA gains at month 12 (+6.34 letters, p=0.07) but poorer final VA (−8.95, p=0.07), while SRF was associated with worse final VA at 12 months (−12.5, p=0.01). At month 3, IRF was associated with a VA decrease at 12 months (−13.7, p=0.02) and lower final VA (−29.8, p<0.001). At month 12, IRF was associated with lower final VA (−11.6, p=0.03). Quantitatively, a reduction of 100 nL of IRF at 3 months was associated with a +1.54 letters gain (p=0.03) in the multivariate analysis. Conclusion: This real-world, multicentre study describes objective baseline fluid volumes that predict visual outcomes at 12 months in routine clinical care. Accurate quantification of baseline fluid volumes may play a predictive role for final visual outcomes.
- 6 December 2025
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología (English Edition)
- Vol. 101 (1) , 502430
New horizons in the treatment of non-infectious uveitis
- 6 December 2025
- Published by Elsevier in Archivos de la Sociedad Española de Oftalmología (English Edition)
- Vol. 101 (1) , 502430
New horizons in the treatment of non-infectious uveitis
- Open Access
- 19 November 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 282, 292-304
Reproductive Life Stages and Female Sex-Specific Patterns in Uveitis Activity: Data From the AIDA Network Uveitis Registry
- 19 November 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 282, 292-304
Open AccessReproductive Life Stages and Female Sex-Specific Patterns in Uveitis Activity: Data From the AIDA Network Uveitis Registry
- 29 May 2024
- Published by BMJ in British Journal of Ophthalmology
- Vol. 108 (12) , 1652-1658
Posner-Schlossman Syndrome European Study Group: study protocol and baseline patients characteristics of a multicentre study
Background The aim of the Posner-Schlossman Syndrome European Study Group (PSS-ESG) is to acquire a comprehensive dataset of European patients with PSS. Here, we present the first report on the study protocol and the clinical findings of the patients at baseline. Methods The PSS-ESG is a retrospective, multicentre study designed to evaluate patients with PSS. The study, designed and driven by a European Expert Committee includes three datasets: (1) the baseline, (2) the follow-up and (3) the intraocular pressure (IOP)/glaucoma dataset. Results A total of 11 centres adhered to the PSS-ESG and 107 patients were included (68 males, 39 females) mostly Caucasian (93.4%). At uveitis onset, the patient’s age ranged between 11 and 76 years, (mean age: 42±15 years). Best-corrected visual acuity was >0.5 in 80.3% of the eyes, IOP was >40 mm Hg in 44% of the eyes. Keratic precipitates were found in 78.5% of the eyes. No flare or cells in anterior chamber were detected in 56% and 53% of the cases, respectively. PCR analysis on aqueous sample was positive for cytomegalovirus-DNA in 50.6% out of the 81 tested patients. Conclusions The PSS-ESG is the first multicentre study aimed to collect a comprehensive dataset of patients with PSS in non-Asian countries. A middlde-aged Caucasian male with a low-grade anterior chamber inflammation, keratic precipitates, preserved visual acuity and marked increased in IOP seemed to be the standard PSS patient across the 11 uveitis and glaucoma centres participating in the PSS-ESG.
- 29 May 2024
- Published by BMJ in British Journal of Ophthalmology
- Vol. 108 (12) , 1652-1658
Posner-Schlossman Syndrome European Study Group: study protocol and baseline patients characteristics of a multicentre study
Background The aim of the Posner-Schlossman Syndrome European Study Group (PSS-ESG) is to acquire a comprehensive dataset of European patients with PSS. Here, we present the first report on the study protocol and the clinical findings of the patients at baseline. Methods The PSS-ESG is a retrospective, multicentre study designed to evaluate patients with PSS. The study, designed and driven by a European Expert Committee includes three datasets: (1) the baseline, (2) the follow-up and (3) the intraocular pressure (IOP)/glaucoma dataset. Results A total of 11 centres adhered to the PSS-ESG and 107 patients were included (68 males, 39 females) mostly Caucasian (93.4%). At uveitis onset, the patient’s age ranged between 11 and 76 years, (mean age: 42±15 years). Best-corrected visual acuity was >0.5 in 80.3% of the eyes, IOP was >40 mm Hg in 44% of the eyes. Keratic precipitates were found in 78.5% of the eyes. No flare or cells in anterior chamber were detected in 56% and 53% of the cases, respectively. PCR analysis on aqueous sample was positive for cytomegalovirus-DNA in 50.6% out of the 81 tested patients. Conclusions The PSS-ESG is the first multicentre study aimed to collect a comprehensive dataset of patients with PSS in non-Asian countries. A middlde-aged Caucasian male with a low-grade anterior chamber inflammation, keratic precipitates, preserved visual acuity and marked increased in IOP seemed to be the standard PSS patient across the 11 uveitis and glaucoma centres participating in the PSS-ESG.